Carlo Ceruti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carlo Ceruti has a total of 177 co-authors. Here are the top co-authors by number of shared publications:
- Luigi Rolle
Divisione Universitaria di Urologia II, Dipartimento di Discipline Medico-Chirurgiche, Ospedale San Giovanni Battista-Molinette, Università degli Studi di Torino, Torino, Italy
16 shared publications Dario Fontana
Molinette General and University Hospital , Torino Italy
10 shared publicationsMassimiliano Timpano
Milan, Italy
9 shared publications- Marco Falcone
Department of Urology, University of Turin, Città della Salute e della Scienza, Turin, Italy
8 shared publications Paolo Destefanis
8 shared publications- Mirko Preto
Department of Urology, University of Turin, Città della Salute e della Scienza, Turin, Italy
7 shared publications
Latest Publications
- 9 October 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (9) , e3319
Surgical Outcomes in Male to Female Penoscrotal Vaginoplasty according to technical improvement and modification: A single center experience
- 9 October 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (9) , e3319
Surgical Outcomes in Male to Female Penoscrotal Vaginoplasty according to technical improvement and modification: A single center experience
- 9 October 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (9) , e3219-e3220
BPH and BPH surgery – related ejaculation disorders: Results from a prospective observational trial
- 9 October 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (9) , e3219-e3220
BPH and BPH surgery – related ejaculation disorders: Results from a prospective observational trial
- Open Access
- 1 January 2018
- Published by SAGE Publications in Tumori Journal
- Vol. 104 (1) , 66-70
Role of perioperative dynamic sentinel node biopsy for cN0 penile cancer management: experience from an Italian tertiary referral center
Purpose: Inguinal lymphadenectomy (iLAD) reduces mortality in patients with cN0 penile cancer but yields high complication rates. Thus, its prophylactic role has been questioned and dynamic sentinel node biopsy (DSNB) was introduced to select men who should undergo the procedure. Our aim was to investigate the accuracy of a contemporary DSNB cohort. Methods: We performed a retrospective analysis of ≥T1 or ≥G2 cN0 penile cancer undergoing perioperative DSNB from June 2009 to June 2015 at a tertiary referral center. We excluded men with <18 months follow-up or with local recurrence after primary curative treatment. Complications were graded according to the Clavien-Dindo classification. Results: Thirty-five men underwent DSNB; 85.71% had ≤T2 penile cancer with ≤G2a histology. Per groin detection rate was 80% (scintigraphy being positive bilaterally in 60% and unilaterally in 20.0%). In no cases did DSNB prolong the postoperative course compared to primary surgery. Nine men (n = 15/109 nodes removed) had positive results, 8 of whom underwent iLAD. Among negative DSNB patients, 2 developed nodal penile cancer recurrence; none of them had node biopsy due to inconclusive scintigraphy. At a median follow-up of 42 months (interquartile range 30-78 months), if considering only men with scintigraphy detected inguinal nodes, per-patient sensitivity and specificity were 50% and 80% whereas positive predictive value and negative predictive value were 25% and 92.3%, respectively. Conclusions: Perioperative DSNB is a safe procedure, yielding promising results when performed at a tertiary referral center. Future prospective large studies are needed to investigate how to optimize detection rate and reduce false-negative rates.
- 1 January 2018
- Published by SAGE Publications in Tumori Journal
- Vol. 104 (1) , 66-70
Open AccessRole of perioperative dynamic sentinel node biopsy for cN0 penile cancer management: experience from an Italian tertiary referral center
Purpose: Inguinal lymphadenectomy (iLAD) reduces mortality in patients with cN0 penile cancer but yields high complication rates. Thus, its prophylactic role has been questioned and dynamic sentinel node biopsy (DSNB) was introduced to select men who should undergo the procedure. Our aim was to investigate the accuracy of a contemporary DSNB cohort. Methods: We performed a retrospective analysis of ≥T1 or ≥G2 cN0 penile cancer undergoing perioperative DSNB from June 2009 to June 2015 at a tertiary referral center. We excluded men with <18 months follow-up or with local recurrence after primary curative treatment. Complications were graded according to the Clavien-Dindo classification. Results: Thirty-five men underwent DSNB; 85.71% had ≤T2 penile cancer with ≤G2a histology. Per groin detection rate was 80% (scintigraphy being positive bilaterally in 60% and unilaterally in 20.0%). In no cases did DSNB prolong the postoperative course compared to primary surgery. Nine men (n = 15/109 nodes removed) had positive results, 8 of whom underwent iLAD. Among negative DSNB patients, 2 developed nodal penile cancer recurrence; none of them had node biopsy due to inconclusive scintigraphy. At a median follow-up of 42 months (interquartile range 30-78 months), if considering only men with scintigraphy detected inguinal nodes, per-patient sensitivity and specificity were 50% and 80% whereas positive predictive value and negative predictive value were 25% and 92.3%, respectively. Conclusions: Perioperative DSNB is a safe procedure, yielding promising results when performed at a tertiary referral center. Future prospective large studies are needed to investigate how to optimize detection rate and reduce false-negative rates.
- 1 April 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (4) , e608
PPTLBA-01 QUALITY OF LIFE AFTER PENILE PROSTHESIS IMPLANTATION – 1 YEAR FOLLOW-UP DATA OF THE ITALIAN PROSPECTIVE REGISTRY INSIST-ED
The impact of penile prosthesis implantation (PPI) on the overall patient's quality of life (QoL) has been scantly analyzed. The aim of this study was to assess the QoL of patients submitted to PPI, using the validated questionnaire Quality of Life and Sexuality with Penile Prosthesis (QoLSPP).
- 1 April 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (4) , e608
PPTLBA-01 QUALITY OF LIFE AFTER PENILE PROSTHESIS IMPLANTATION – 1 YEAR FOLLOW-UP DATA OF THE ITALIAN PROSPECTIVE REGISTRY INSIST-ED
The impact of penile prosthesis implantation (PPI) on the overall patient's quality of life (QoL) has been scantly analyzed. The aim of this study was to assess the QoL of patients submitted to PPI, using the validated questionnaire Quality of Life and Sexuality with Penile Prosthesis (QoLSPP).
- Open Access
- 1 September 2016
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery - Global Open
- Vol. 4 (9) , e857
Reconstruction Approach to a Rare Case of Acquired Scrotal Giant Muscular Hamartoma
Acquired scrotal giant muscular hamartoma is an uncommon benign lesion with fewer than 10 documented cases all over the world. It is characterized by a proliferation of dermal smooth muscle bundles of scrotum dartos fascia. The authors report a rare case of acquired scrotal giant muscular hamartoma, which occurred in a 70-year-old severely obese and diabetic man presenting with a progressive scrotal enlargement and swelling in the last year, causing marked reduction in quality of life and cosmetic problems. The patient underwent a wide excision of the hamartomatous lesion, and then, a reductive scrotoplasty and autologous skin grafting of penis were performed. Anatomopathological examination showed an acquired scrotal giant muscular hamartoma arising from muscular fascia of dartos. This surgical technique is a valid, safe, effective, and minimally invasive option to treat this pathology, achieving both excellent functional and aesthetic results, with a marked improvement of the patient’s quality of life.
- 1 September 2016
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery - Global Open
- Vol. 4 (9) , e857
Open AccessReconstruction Approach to a Rare Case of Acquired Scrotal Giant Muscular Hamartoma
Acquired scrotal giant muscular hamartoma is an uncommon benign lesion with fewer than 10 documented cases all over the world. It is characterized by a proliferation of dermal smooth muscle bundles of scrotum dartos fascia. The authors report a rare case of acquired scrotal giant muscular hamartoma, which occurred in a 70-year-old severely obese and diabetic man presenting with a progressive scrotal enlargement and swelling in the last year, causing marked reduction in quality of life and cosmetic problems. The patient underwent a wide excision of the hamartomatous lesion, and then, a reductive scrotoplasty and autologous skin grafting of penis were performed. Anatomopathological examination showed an acquired scrotal giant muscular hamartoma arising from muscular fascia of dartos. This surgical technique is a valid, safe, effective, and minimally invasive option to treat this pathology, achieving both excellent functional and aesthetic results, with a marked improvement of the patient’s quality of life.
- Open Access
- 17 July 2015
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 9 (7-8) , 423-7
Sexual function after surgical treatment for penile cancer: Which organ-sparing approach gives the best results?
Introduction: We compared the postoperative sexual function of patients who underwent wide local excision (WLE) and glansectomy with urethral glanduloplasty for penile cancer.Methods: We retrospectively reviewed clinical data of 41 patients affected by superficial, localized penile cancer (≤cT2a) between 2006 and 2013. Patients with severe erectile dysfunction and not interested in resuming an active sexual life were selected for penile partial amputation. Patients with preoperative satisfying erectile function and concerned about the preservation of their sexual potency were scheduled for WLE (Group A) or glansectomy with urethral glanduloplasty (Group B). Sexual function was assessed with the International Index of Erectile Function (IIEF) questionnaire and the Sex Encounter Profile (SEP). At 1 year, patients were asked to complete the questionnaires again and were questioned about their genital sensibility and ejaculatory reflex persistence. Postoperative complications were reported according to the Clavien-Dindo classification. Statistical analysis was performed by two-tailed test: Student t-test and chi-square.Results: Among the 41 patients enrolled, 12 underwent WLE (29.2%), 23 glansectomy with urethral glanduloplasty (56%) and 6 with penile partial amputation (14.6%). A decrease in postoperative IIEF was recorded in both groups, but was statistically significant only in Group B (p = 0.003). As for the SEP, while no significant changes were recorded postoperatively in Group A, a marked reduction was reported for Group B, with a statistically significant decrease in the possibility of achieving penetrative intercourse (p = 0.006) and in the perceived satisfaction during sexual activity (p = 0.004).Conclusions: WLE lead to better sexual outcomes and less postoperative complications as compared to glansectomy with urethral glanduloplasty.
- 17 July 2015
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 9 (7-8) , 423-7
Open AccessSexual function after surgical treatment for penile cancer: Which organ-sparing approach gives the best results?
Introduction: We compared the postoperative sexual function of patients who underwent wide local excision (WLE) and glansectomy with urethral glanduloplasty for penile cancer.Methods: We retrospectively reviewed clinical data of 41 patients affected by superficial, localized penile cancer (≤cT2a) between 2006 and 2013. Patients with severe erectile dysfunction and not interested in resuming an active sexual life were selected for penile partial amputation. Patients with preoperative satisfying erectile function and concerned about the preservation of their sexual potency were scheduled for WLE (Group A) or glansectomy with urethral glanduloplasty (Group B). Sexual function was assessed with the International Index of Erectile Function (IIEF) questionnaire and the Sex Encounter Profile (SEP). At 1 year, patients were asked to complete the questionnaires again and were questioned about their genital sensibility and ejaculatory reflex persistence. Postoperative complications were reported according to the Clavien-Dindo classification. Statistical analysis was performed by two-tailed test: Student t-test and chi-square.Results: Among the 41 patients enrolled, 12 underwent WLE (29.2%), 23 glansectomy with urethral glanduloplasty (56%) and 6 with penile partial amputation (14.6%). A decrease in postoperative IIEF was recorded in both groups, but was statistically significant only in Group B (p = 0.003). As for the SEP, while no significant changes were recorded postoperatively in Group A, a marked reduction was reported for Group B, with a statistically significant decrease in the possibility of achieving penetrative intercourse (p = 0.006) and in the perceived satisfaction during sexual activity (p = 0.004).Conclusions: WLE lead to better sexual outcomes and less postoperative complications as compared to glansectomy with urethral glanduloplasty.
- 1 January 2014
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 11 (1) , 312
Does Sex Reassignment Surgery Induce Cerebral Modifications in MTF Transsexuals?
- 1 January 2014
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 11 (1) , 312
Does Sex Reassignment Surgery Induce Cerebral Modifications in MTF Transsexuals?
- 1 November 2013
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 10 (11) , 2798-2814
Phosphodiesterase Type 5 Inhibitor Treatment for Erectile Dysfunction in Patients with End-Stage Renal Disease Receiving Dialysis or After Renal Transplantation
Introduction: The phosphodiesterase type 5 (PDE5) inhibitors are generally well tolerated and effective for treating erectile dysfunction (ED), including in patients with significant comorbidity. Because of this benign safety profile, investigators have used PDE5 inhibitors to treat patients with ED and severe renal disease or those who have received renal transplants. Aim: To assess safety and efficacy of PDE5 inhibitors in patients receiving dialysis or renal transplants. Main Outcome Measures: Erectile function as assessed by the International Index of Erectile Function (IIEF) and Global Assessment Questions; adverse events (AEs). Methods: We reviewed published studies of PDE5 inhibitors in patients receiving dialysis or renal transplants. Results: In double-blind, placebo-controlled studies in patients receiving dialysis or renal transplants, sildenafil significantly improved erectile function as assessed by the IIEF, and 75–85% of patients reported improved erectile function on Global Assessment Questions; efficacy was more variable in less well-controlled studies. In >260 patients undergoing dialysis who received sildenafil in clinical studies, there were only six reported discontinuations because of AEs (headache [N=3], headache and nausea [N=1], gastrointestinal [N=1], and symptomatic blood pressure decrease [N=1]). In approximately 400 patients with renal transplants who received sildenafil, only three patients discontinued because of AEs. Vardenafil improved IIEF scores of up to 82% of renal transplant recipients in randomized, controlled studies (N=59, total), with no reported discontinuations because of AEs. Limited data also suggest benefit with tadalafil. Conclusions: ED is common in patients undergoing renal dialysis or postrenal transplant and substantially affects patient quality of life. Sildenafil and vardenafil appear to be efficacious and well tolerated in patients receiving renal dialysis or transplant.
- 1 November 2013
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 10 (11) , 2798-2814
Phosphodiesterase Type 5 Inhibitor Treatment for Erectile Dysfunction in Patients with End-Stage Renal Disease Receiving Dialysis or After Renal Transplantation
Introduction: The phosphodiesterase type 5 (PDE5) inhibitors are generally well tolerated and effective for treating erectile dysfunction (ED), including in patients with significant comorbidity. Because of this benign safety profile, investigators have used PDE5 inhibitors to treat patients with ED and severe renal disease or those who have received renal transplants. Aim: To assess safety and efficacy of PDE5 inhibitors in patients receiving dialysis or renal transplants. Main Outcome Measures: Erectile function as assessed by the International Index of Erectile Function (IIEF) and Global Assessment Questions; adverse events (AEs). Methods: We reviewed published studies of PDE5 inhibitors in patients receiving dialysis or renal transplants. Results: In double-blind, placebo-controlled studies in patients receiving dialysis or renal transplants, sildenafil significantly improved erectile function as assessed by the IIEF, and 75–85% of patients reported improved erectile function on Global Assessment Questions; efficacy was more variable in less well-controlled studies. In >260 patients undergoing dialysis who received sildenafil in clinical studies, there were only six reported discontinuations because of AEs (headache [N=3], headache and nausea [N=1], gastrointestinal [N=1], and symptomatic blood pressure decrease [N=1]). In approximately 400 patients with renal transplants who received sildenafil, only three patients discontinued because of AEs. Vardenafil improved IIEF scores of up to 82% of renal transplant recipients in randomized, controlled studies (N=59, total), with no reported discontinuations because of AEs. Limited data also suggest benefit with tadalafil. Conclusions: ED is common in patients undergoing renal dialysis or postrenal transplant and substantially affects patient quality of life. Sildenafil and vardenafil appear to be efficacious and well tolerated in patients receiving renal dialysis or transplant.